Literature DB >> 19194646

Comorbid substance abuse and brain morphology in recent-onset psychosis.

Thomas Wobrock1, Helmut Sittinger, Bernd Behrendt, Roberto D'Amelio, Peter Falkai.   

Abstract

The aim of the presented study was to compare schizophrenia and schizoaffective patients early in the course of the disease with and without comorbid substance abuse disorder (SUD vs. NSUD) with regard to brain morphology. In a prospective design 41 patients (20 SUD vs. 21 NSUD) diagnosed as recent-onset schizophrenia or schizoaffective disorder consecutively admitted to hospital received standardized psychopathological evaluation (BPRS, SANS, MADRS, CGI, GAF) and MRI scanning with volumetric measurement of superior temporal gyrus (STG), amygdala-hippocampal complex, and cingulum. Patients with SUD (primarily cannabis) were significantly younger, predominantly male and had a lower socioeconomic status. Despite less attentional impairment (SANS subscore) and elevated anxiety/depression (BPRS subscore) in patients with SUD compared to NSUD, no other psychopathological differences could be detected. There were no differences in the assessed temporolimbic brain morphology between the two subgroups. In conclusion, in this study substance abuse in recent-onset psychosis had no effect on brain morphology and the earlier onset of psychosis in patients with comorbid SUD could not be explained by supposed accentuated brain abnormalities in temporolimbic regions.

Entities:  

Mesh:

Year:  2009        PMID: 19194646      PMCID: PMC3085762          DOI: 10.1007/s00406-008-0831-x

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  65 in total

1.  Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study.

Authors:  Stanley Zammit; Peter Allebeck; Sven Andreasson; Ingvar Lundberg; Glyn Lewis
Journal:  BMJ       Date:  2002-11-23

2.  Cannabis and brain morphology in recent-onset schizophrenia.

Authors:  W Cahn; H E Hulshoff Pol; E Caspers; N E M van Haren; H G Schnack; R S Kahn
Journal:  Schizophr Res       Date:  2004-04-01       Impact factor: 4.939

3.  Brain volume changes in first-episode schizophrenia: a 1-year follow-up study.

Authors:  Wiepke Cahn; Hilleke E Hulshoff Pol; Elleke B T E Lems; Neeltje E M van Haren; Hugo G Schnack; Jeroen A van der Linden; Patricia F Schothorst; Herman van Engeland; René S Kahn
Journal:  Arch Gen Psychiatry       Date:  2002-11

Review 4.  Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature.

Authors:  Jonathan P Lacro; Laura B Dunn; Christian R Dolder; Susan G Leckband; Dilip V Jeste
Journal:  J Clin Psychiatry       Date:  2002-10       Impact factor: 4.384

Review 5.  Studies of individuals with schizophrenia never treated with antipsychotic medications: a review.

Authors:  E Fuller Torrey
Journal:  Schizophr Res       Date:  2002-12-01       Impact factor: 4.939

6.  Compounded brain volume deficits in schizophrenia-alcoholism comorbidity.

Authors:  Daniel H Mathalon; Adolf Pfefferbaum; Kelvin O Lim; Margaret J Rosenbloom; Edith V Sullivan
Journal:  Arch Gen Psychiatry       Date:  2003-03

7.  Temporolimbic volume reductions in schizophrenia.

Authors:  R E Gur; B I Turetsky; P E Cowell; C Finkelman; V Maany; R I Grossman; S E Arnold; W B Bilker; R C Gur
Journal:  Arch Gen Psychiatry       Date:  2000-08

8.  Smaller anterior hippocampal formation volume in antipsychotic-naive patients with first-episode schizophrenia.

Authors:  Philip R Szeszko; Ethan Goldberg; Handan Gunduz-Bruce; Manzar Ashtari; Delbert Robinson; Anil K Malhotra; Todd Lencz; John Bates; David T Crandall; John M Kane; Robert M Bilder
Journal:  Am J Psychiatry       Date:  2003-12       Impact factor: 18.112

9.  Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes.

Authors:  G Bersani; V Orlandi; G D Kotzalidis; P Pancheri
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2002-04       Impact factor: 5.270

10.  Brain morphological abnormality in schizophrenia is independent of country of origin.

Authors:  S E Chua; I W S Lam; K-S Tai; C Cheung; W-N Tang; E Y H Chen; P W H Lee; F-L Chan; F Lieh-Mak; P J McKenna
Journal:  Acta Psychiatr Scand       Date:  2003-10       Impact factor: 6.392

View more
  15 in total

1.  Auditory mismatch negativity deficits in long-term heavy cannabis users.

Authors:  Patrik Roser; Beate Della; Christine Norra; Idun Uhl; Martin Brüne; Georg Juckel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-02-02       Impact factor: 5.270

2.  Impact of substance use disorder on gray matter volume in schizophrenia.

Authors:  Margaret Quinn; Maureen McHugo; Kristan Armstrong; Neil Woodward; Jennifer Blackford; Stephan Heckers
Journal:  Psychiatry Res Neuroimaging       Date:  2018-08-03       Impact factor: 2.376

Review 3.  Neuroimaging Studies in Patients With Mental Disorder and Co-occurring Substance Use Disorder: Summary of Findings.

Authors:  Kaloyan Rumenov Stoychev
Journal:  Front Psychiatry       Date:  2019-10-23       Impact factor: 4.157

4.  Brain volume in male patients with recent onset schizophrenia with and without cannabis use disorders.

Authors:  Laura Koenders; Marise W J Machielsen; F J van der Meer; Angelique C M van Gasselt; Carin J Meijer; Wim van den Brink; Maarten W J Koeter; Matthan W A Caan; Janna Cousijn; Anouk den Braber; Dennis van 't Ent; Maaike M Rive; Aart H Schene; Elsmarieke van de Giessen; Chaim Huyser; Bart P de Kwaasteniet; Dick J Veltman; Lieuwe de Haan
Journal:  J Psychiatry Neurosci       Date:  2015-05       Impact factor: 6.186

5.  Reduced prefrontal gyrification in obsessive-compulsive disorder.

Authors:  Thomas Wobrock; Oliver Gruber; Andrew M McIntosh; Susanne Kraft; Anne Klinghardt; Harald Scherk; Wolfgang Reith; Thomas Schneider-Axmann; Stephen M Lawrie; Peter Falkai; Thomas William Moorhead
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-01-29       Impact factor: 5.270

6.  Effects of cannabis and familial loading on subcortical brain volumes in first-episode schizophrenia.

Authors:  Berend Malchow; Alkomiet Hasan; Thomas Schneider-Axmann; Alexander Jatzko; Oliver Gruber; Andrea Schmitt; Peter Falkai; Thomas Wobrock
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-10-02       Impact factor: 5.270

7.  MAPK14 and CNR1 gene variant interactions: effects on brain volume deficits in schizophrenia patients with marijuana misuse.

Authors:  O E Onwuameze; K W Nam; E A Epping; T H Wassink; S Ziebell; N C Andreasen; B-C Ho
Journal:  Psychol Med       Date:  2012-07-31       Impact factor: 7.723

Review 8.  Effects of cannabis use on human brain structure in psychosis: a systematic review combining in vivo structural neuroimaging and post mortem studies.

Authors:  Charlotte Rapp; Hilal Bugra; Anita Riecher-Rössler; Corinne Tamagni; Stefan Borgwardt
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

9.  Cannabis use and cognition in schizophrenia.

Authors:  Else-Marie Løberg; Kenneth Hugdahl
Journal:  Front Hum Neurosci       Date:  2009-11-24       Impact factor: 3.169

10.  An fMRI Study of Neuronal Activation in Schizophrenia Patients with and without Previous Cannabis Use.

Authors:  Else-Marie Løberg; Merethe Nygård; Jan Øystein Berle; Erik Johnsen; Rune A Kroken; Hugo A Jørgensen; Kenneth Hugdahl
Journal:  Front Psychiatry       Date:  2012-10-30       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.